If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A cancer vaccine composed of HLA-*2402-restricted epitopic peptides derived from three cancer/testis (CT) antigens, with potential antineoplastic activity. Upon subcutaneous administration, HLA-A*2402-restricted multipeptide vaccine S-488410 may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing these CT antigens. CT antigens, normally expressed only in germ cells of the testis, are overexpressed in a wide variety of human cancers. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
